Medicare payment in January helps MD Anderson reduce its operating losses

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center reduced its year-to-date operating loss to $77.3 million in January, the fifth month of the fiscal year.

In January, the cumulative operating loss was $169.4 million. The loss shrunk because in January MD Anderson booked about $63.4 million in a settlement from Medicare, which allowed the cancer center to claim a portion of its expenses for implementing the Epic system.

Due to increased clinical activity by about 10 percent from December to January, operating revenues were around $28.7 million. This the first monthly positive margin since Epic’s rollout in March 2016.

In an interview with The Cancer Letter, MD Anderson Chief Operating Officer Steve Hahn said the installation, which he described as the largest in the history of Epic, changed over the cancer center’s inpatient, outpatient and billing systems at the same time.

Hahn, deputy to the president, said the installation of Epic exposed and exacerbated inefficiencies in the cancer center’s operations.

The text of the interview with Hahn appears here.

The cancer center’s financials appear below:

MD Anderson Cancer Center Monthly Financials,
September 2016 to January 2017

MDACC-1

Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login